These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19145988)

  • 41. Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells.
    Kim YC; Zhang AH; Yoon J; Culp WE; Lees JR; Wucherpfennig KW; Scott DW
    J Autoimmun; 2018 Aug; 92():77-86. PubMed ID: 29857928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The immunopathology of acute experimental allergic encephalomyelitis induced with myelin proteolipid protein. T cell receptors in inflammatory lesions.
    Sobel RA; Kuchroo VK
    J Immunol; 1992 Aug; 149(4):1444-51. PubMed ID: 1380045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis.
    Tietz S; Périnat T; Greene G; Enzmann G; Deutsch U; Adams R; Imhof B; Aurrand-Lions M; Engelhardt B
    Brain Behav Immun; 2018 Oct; 73():3-20. PubMed ID: 29920328
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of murine experimental autoimmune encephalomyelitis by interleukin-2 receptor targeted fusion toxin, DAB(389)IL-2.
    Phillips SM; Bhopale MK; Hilliard B; Zekavat SA; Ali MA; Rostami A
    Cell Immunol; 2010; 261(2):144-52. PubMed ID: 20042183
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection.
    Benedek G; Meza-Romero R; Jordan K; Keenlyside L; Offner H; Vandenbark AA
    J Neuroinflammation; 2015 Jun; 12():123. PubMed ID: 26104759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
    Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
    Feinstein DL; Galea E; Gavrilyuk V; Brosnan CF; Whitacre CC; Dumitrescu-Ozimek L; Landreth GE; Pershadsingh HA; Weinberg G; Heneka MT
    Ann Neurol; 2002 Jun; 51(6):694-702. PubMed ID: 12112074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuroprotection and neuroregeneration in multiple sclerosis.
    Stangel M
    J Neurol; 2008 Dec; 255 Suppl 6():77-81. PubMed ID: 19300964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.
    Elliott EA; McFarland HI; Nye SH; Cofiell R; Wilson TM; Wilkins JA; Squinto SP; Matis LA; Mueller JP
    J Clin Invest; 1996 Oct; 98(7):1602-12. PubMed ID: 8833909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
    Aktas O; Kieseier B; Hartung HP
    Trends Neurosci; 2010 Mar; 33(3):140-52. PubMed ID: 20045200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Delineation of the minimal encephalitogenic epitope within the immunodominant region of myelin oligodendrocyte glycoprotein: diverse V beta gene usage by T cells recognizing the core epitope encephalitogenic for T cell receptor V beta b and T cell receptor V beta a H-2b mice.
    Mendel Kerlero de Rosbo N; Ben-Nun A
    Eur J Immunol; 1996 Oct; 26(10):2470-9. PubMed ID: 8898962
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fundamental differences in the dynamics of CNS lesion development and composition in MP4- and MOG peptide 35-55-induced experimental autoimmune encephalomyelitis.
    Kuerten S; Javeri S; Tary-Lehmann M; Lehmann PV; Angelov DN
    Clin Immunol; 2008 Nov; 129(2):256-67. PubMed ID: 18722816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tropisetron diminishes demyelination and disease severity in an animal model of multiple sclerosis.
    Aminian A; Noorbakhsh F; Ghazi-Khansari M; Kafami L; Javadi S; Hassanzadeh G; Rahimian R; Dehpour AR; Mehr SE
    Neuroscience; 2013 Sep; 248():299-306. PubMed ID: 23774631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis.
    Weinberg AD; Wegmann KW; Funatake C; Whitham RH
    J Immunol; 1999 Feb; 162(3):1818-26. PubMed ID: 9973447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease.
    Ben-Nun A; Mendel I; Bakimer R; Fridkis-Hareli M; Teitelbaum D; Arnon R; Sela M; Kerlero de Rosbo N
    J Neurol; 1996 Apr; 243(4 Suppl 1):S14-22. PubMed ID: 8965116
    [TBL] [Abstract][Full Text] [Related]  

  • 57. You-Gui pills promote nerve regeneration by regulating netrin1, DCC and Rho family GTPases RhoA, Racl, Cdc42 in C57BL/6 mice with experimental autoimmune encephalomyelitis.
    Ji X; Liu H; An C; Wang Y; Zhao H; Zhang Q; Li M; Qi F; Chen Z; Wang X; Wang L
    J Ethnopharmacol; 2016 Jul; 187():123-33. PubMed ID: 27106785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models.
    Neil S; Huh J; Baronas V; Li X; McFarland HF; Cherukuri M; Mitchell JB; Quandt JA
    Brain Behav Immun; 2017 May; 62():332-343. PubMed ID: 28238951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.
    Gilgun-Sherki Y; Panet H; Melamed E; Offen D
    Brain Res; 2003 Nov; 989(2):196-204. PubMed ID: 14556941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
    de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J
    Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.